Company intelligence
ten23 health
Sterile Solutions, Built Differently.
About ten23 health
ten23 health is the human-centric and sustainable strategic partner of choice for the pharmaceutical industry and biotech start-ups for the development, manufacture, and testing of tomorrow’s medicines. Our sites in Visp and Basel 🇨🇭 support our clients in developing differentiated, stable, usable, and safe injectable treatments for patients. More about us: www.ten23.health Subscribe our newsletter: www.ten23.health/ten23-health-newsletter
Verified activity
Signals from ten23 health
7 published signals
Research & Knowledge
ten23 health integrated formulation development, analytical sciences, process development, primary packaging and device expertise and aseptic manufacturing to help partners de-risk complex biologic drug products from early development through GMP manufacturing.
Reported by ten23 health
Legal & Regulatory
ten23 health became the first sterile drug product CDMO to achieve B Corp certification in September 2024.
Reported by ten23 health
Legal & Regulatory
ten23 health achieved B Corp certification and was ranked in the top 3% of its industry on EcoVadis.
Reported by ten23 health
Customers & Market
ten23 health partners from formulation through GMP fill/finish and release, high-concentration formulation, SC delivery, PFS/PFC and auto-injector integration and assembly participated in the Nordics Early Stage Biologics Innovation NLS Days 2026 event in Stockholm.
Reported by Adithya Balasubramanian
Research & Knowledge
ten23 health published a peer-reviewed study in the Journal of Pharmaceutical Sciences evaluating single-use mixing technologies for protein products.
Reported by ten23 health
Presence & Recognition
ten23 health hosted the Healthcare Collective B Lab at Basel on 10 November 2026.
Reported by Hanns-Christian Mahler
Strategy & Corporate Development
ten23 health expanded from its launch in 2021 with the integration of Swissfillon into a global sterile drug product CDMO, opening the VIVA2 facility, achieving B Corp certification, launching robot-assisted Line 0 filling, and adding ATMP GMP capabilities and expanding into Japan.
Reported by Hanns-Christian Mahler